Recombinant Human GM-CSF/CSF2 Protein (HEK293 Cells)

Specifications

Catalog number

PKSH031982

Size / count

20 µg

Dry ice

No

Hazardous

No

Discontinued

No

Background

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 immune responses in cognate T cells. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients.

Synonyms

CSF; CSF2; Colony-Stimulating Factor; GM-CSF; GMCSF; Granulocyte-Macrophage Colony-Stimulating Factor; Molgramostin; Sargramostim

UniProt

P04141

Accession Number

NP_000749.2

Expression System

HEK293 Cells

Tag

None

Sequence

Met 1-Glu144

Applications

Cell culture

Field of Research

Immunology

Endotoxin

< 1.0 EU per μg of the protein as determined by the LAL method.

Purity

> 90 % as determined by reducing SDS-PAGE.

Bioactivity

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 0.1-0.6 ng/ml.

Reconstitution

Please refer to the printed manual for detailed information.

Shipping Conditions

This product is provided as lyophilized powder which is shipped with ice packs.

Storage Conditions

Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Calculated Molecular Weight

14.5 kDa

Observed Molecular Weight

23.8 kDa

Species

Human